{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:28:49Z","timestamp":1787135329787,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This single-center subgroup analysis of a prospective trial (NCT04571086) at University Hospital Essen investigated tumor uptake and detection rates of [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-FAPI-46- versus [\n                    <jats:sup>18<\/jats:sup>\n                    F]FDG PET in triple-negative breast cancer (TNBC) patients undergoing initial or follow-up staging. Lesions were recorded across anatomical regions, with detection efficacy, uptake values, tumor-to-liver ratios, and tumor volumes assessed. 22 patients were included (initial-\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910, follow-up staging\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). No significant difference in region-based detection rates was observed between [\n                    <jats:sup>18<\/jats:sup>\n                    F]FDG- (93%, 53\/57 regions) and [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-FAPI-46 PET (93%, 53\/57 regions) (McNemar\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20091.0). Three patients (25%) at follow-up staging showed an average tumor SUV\n                    <jats:sub>mean<\/jats:sub>\n                    \u22655 on [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-FAPI-46 PET; 2\/3 showed SUV\n                    <jats:sub>max<\/jats:sub>\n                    &gt;10 in most lesions. Mean tumor volume was higher for [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-FAPI-46, though not statistically significant at initial- (50.1\u2009\u00b1\u2009120.8 mL vs. 11.9\u2009\u00b1\u200918.5 mL) and follow-up staging (102.2\u2009\u00b1\u2009122.3 mL vs. 79.0\u2009\u00b1\u200990.4 mL). [\u2076\u2078Ga]Ga-FAPI-46 PET demonstrated comparable detection in TNBC; high tumor uptake in a subset, supporting its theranostic potential.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-61253-8","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:27:10Z","timestamp":1785752830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of [68Ga]Ga-FAPI-46 PET in comparison to [18F]FDG PET in triple-negative breast cancer and potential for theranostic application"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4380-1629","authenticated-orcid":false,"given":"Alina Toni","family":"K\u00fcper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Ciuciulkaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Carrilho","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra Antonia","family":"Mavroeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Demmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Magaly","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Djaileb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Peter","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"61253_CR1","doi-asserted-by":"publisher","unstructured":"Siegel Mph, R. L. et al. Cancer statistics, 2023; (2023). https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"61253_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00330-013-3037-1","volume":"24","author":"HR Koo","year":"2014","unstructured":"Koo, H. R. et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur. Radiol. 24, 610\u20138. https:\/\/doi.org\/10.1007\/s00330-013-3037-1 (2014).","journal-title":"Eur. Radiol."},{"key":"61253_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux, D. et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 38, 426\u2013435. https:\/\/doi.org\/10.1007\/s00259-010-1640-9 (2011).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR4","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz, S. C. et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 51, 2706\u20132732. https:\/\/doi.org\/10.1007\/s00259-024-06696-9 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019 (2021).","journal-title":"Ann. Oncol."},{"key":"61253_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar, W. J. et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 20, 691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"61253_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","volume":"18","author":"N Avril","year":"2000","unstructured":"Avril, N. et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J. Clin. Oncol. 18, 3495\u2013502. https:\/\/doi.org\/10.1200\/JCO.2000.18.20.3495 (2000).","journal-title":"J. Clin. Oncol."},{"key":"61253_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cpet.2023.02.006","volume":"18","author":"K L\u00fcckerath","year":"2023","unstructured":"L\u00fcckerath, K., Trajkovic-Arsic, M. & Mona, C. E. Fibroblast Activation Protein Inhibitor Theranostics. PET. Clin. 18, 409\u2013418. https:\/\/doi.org\/10.1016\/j.cpet.2023.02.006 (2023).","journal-title":"PET. Clin."},{"key":"61253_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030908","volume":"15","author":"S Taralli","year":"2023","unstructured":"Taralli, S. et al. PET\/CT with fibroblast activation protein inhibitors in breast cancer: Diagnostic and theranostic application\u2014A literature review. Cancers (Basel) 15, 908. https:\/\/doi.org\/10.3390\/cancers15030908 (2023).","journal-title":"Cancers (Basel)"},{"key":"61253_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner, T. et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J. Nucl. Med. 59, 1415\u20131422. https:\/\/doi.org\/10.2967\/jnumed.118.210443 (2018).","journal-title":"J. Nucl. Med."},{"key":"61253_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116683","volume":"10","author":"F Liu","year":"2015","unstructured":"Liu, F. et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: A meta-analysis. PLoS One 10, e0116683. https:\/\/doi.org\/10.1371\/journal.pone.0116683 (2015).","journal-title":"PLoS One"},{"key":"61253_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel, F. L. et al. Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J. Nucl. Med. 60, 386\u2013392. https:\/\/doi.org\/10.2967\/jnumed.118.215913 (2019).","journal-title":"J. Nucl. Med."},{"key":"61253_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.21663","volume":"71","author":"AB Olawaiye","year":"2021","unstructured":"Olawaiye, A. B., Baker, T. P., Washington, M. K. & Mutch, D. G. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J. Clin. 71, 287\u2013298. https:\/\/doi.org\/10.3322\/caac.21663 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"61253_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O, J. H., Lodge, M. A. & Wahl, R. L. Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0. Radiology 280, 576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043 (2016).","journal-title":"Radiology"},{"key":"61253_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging. 42, 328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR16","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler, W. P. et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin. Cancer Res. 28, 4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1432 (2022).","journal-title":"Clin. Cancer Res."},{"key":"61253_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/RLU.0000000000003905","volume":"47","author":"Q Wang","year":"2022","unstructured":"Wang, Q., Tang, W., Cai, L. & Chen, Y. Non-18F-FDG-Avid Intrahepatic Metastasis of Breast Cancer Revealed by 68Ga-FAPI PET\/CT. Clin. Nucl. Med. 47, 228\u2013230. https:\/\/doi.org\/10.1097\/RLU.0000000000003905 (2022).","journal-title":"Clin. Nucl. Med."},{"key":"61253_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00259-024-06866-9","volume":"52","author":"L Filippi","year":"2024","unstructured":"Filippi, L., Urso, L., Ferrari, C., Guglielmo, P. & Evangelista, L. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur. J. Nucl. Med. Mol. Imaging. 52, 263\u2013279. https:\/\/doi.org\/10.1007\/s00259-024-06866-9 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/S12149-021-01616-5","volume":"35","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek, H. et al. 68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT. Ann. Nucl. Med. Springer Japan. 35, 744\u2013752. https:\/\/doi.org\/10.1007\/S12149-021-01616-5 (2021).","journal-title":"Ann. Nucl. Med. Springer Japan"},{"key":"61253_CR20","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging. 47, 1820\u20131832. https:\/\/doi.org\/10.1007\/s00259-020-04769-z (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","volume":"35","author":"U Elboga","year":"2021","unstructured":"Elboga, U. et al. Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer. Ann. Nucl. Med. 35, 1321\u20131331. https:\/\/doi.org\/10.1007\/s12149-021-01672-x (2021).","journal-title":"Ann. Nucl. Med."},{"key":"61253_CR22","doi-asserted-by":"publisher","unstructured":"Shang, Q., Hao, B., Xu, W. & Meng, T. Pang \u00b7 Yizhen, Sun \u00b7 Long, et al. Ga-FAPI PET\/CT detected non-FDG-avid bone metastases in breast cancer. Eur J Nucl Med Mol Imaging [Internet]. https:\/\/doi.org\/10.1007\/s00259-021-05664-x","DOI":"10.1007\/s00259-021-05664-x"},{"key":"61253_CR23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262468","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus, J. et al. Initial clinical experience with 90 Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.121.262468 (2021). jnumed.121.262468.","journal-title":"J. Nucl. Med."},{"key":"61253_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.121.262808","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler, L. et al. Pitfalls and Common Findings in 68 Ga-FAPI PET: A Pictorial Analysis. J. Nucl. Med. 63, 890\u2013896. https:\/\/doi.org\/10.2967\/jnumed.121.262808 (2022).","journal-title":"J. Nucl. Med."},{"key":"61253_CR25","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1097\/RLU.0000000000003796","volume":"47","author":"S Gungor","year":"2022","unstructured":"Gungor, S. & Sel\u00e7uk, N. A. Benign bone cyst mimicking bone metastasis demonstrated on 68Ga-FAPI. Clin. Nucl. Med. 47, e95-7. https:\/\/doi.org\/10.1097\/RLU.0000000000003796 (2022).","journal-title":"Clin. Nucl. Med."},{"key":"61253_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4274\/mirt.galenos.2022.80774","volume":"32","author":"G Tatar","year":"2023","unstructured":"Tatar, G. et al. 68Ga-FAPI-04 PET\/CT Findings in Patients with Liver Cirrhosis. Mol. Imaging Radionucl. Ther. 32, 146\u2013149. https:\/\/doi.org\/10.4274\/mirt.galenos.2022.80774 (2023).","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"61253_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.11.015","author":"M Bentestuen","year":"2025","unstructured":"Bentestuen, M., Dahlsgaard-Wallenius, S., Stolberg, M. M. K. & Zacho, H. D. Nonmalignant findings on FAPI PET: An updated rapid systematic review of the literature. Semin Nucl. Med. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.015 (2025).","journal-title":"Semin Nucl. Med."},{"key":"61253_CR28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.123.266981","volume":"65","author":"M Watanabe","year":"2024","unstructured":"Watanabe, M. et al. Prognostic implications of 68 Ga-FAPI-46 PET\/CT\u2013derived parameters on overall survival in various types of solid tumors. J. Nucl. Med. 65, 1027\u201334. https:\/\/doi.org\/10.2967\/jnumed.123.266981 (2024).","journal-title":"J. Nucl. Med."},{"key":"61253_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040597","volume":"13","author":"B Hadebe","year":"2023","unstructured":"Hadebe, B., Harry, L., Ebrahim, T., Pillay, V. & Vorster, M. The role of PET\/CT in breast cancer. Diagnostics 13, 597. https:\/\/doi.org\/10.3390\/diagnostics13040597 (2023).","journal-title":"Diagnostics"},{"key":"61253_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-015-3558-1","volume":"153","author":"Y Yue","year":"2015","unstructured":"Yue, Y. et al. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET\/CT imaging. Breast Cancer Res. Treat. 153, 607\u2013616. https:\/\/doi.org\/10.1007\/s10549-015-3558-1 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"61253_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00259-016-3402-9","volume":"43","author":"GA Ulaner","year":"2016","unstructured":"Ulaner, G. A. et al. 18F-FDG-PET\/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 43, 1937\u20131944. https:\/\/doi.org\/10.1007\/s00259-016-3402-9 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"61253_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.122.264871","volume":"64","author":"P Backhaus","year":"2023","unstructured":"Backhaus, P. et al. Initial Results of 68 Ga-FAPI-46 PET\/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer. J. Nucl. Med. 64, 717\u2013723. https:\/\/doi.org\/10.2967\/jnumed.122.264871 (2023).","journal-title":"J. Nucl. Med."},{"key":"61253_CR33","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s00432-022-04250-4","volume":"149","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 149, 3469\u20133483. https:\/\/doi.org\/10.1007\/s00432-022-04250-4 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"61253_CR34","unstructured":"Tianxin Liu, J. L. J. L. S. X. and JY. [18F]AlF-NOTA-FAPI-04 PET\/CT Uptake of the Primary Tumor on PET\/CT Imaging Might Distinguish Triple Negative Breast Cancer. J. Nucl. Med. 65 (2) (2024)."},{"key":"61253_CR35","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jnci\/djab121","volume":"114","author":"SS Badve","year":"2022","unstructured":"Badve, S. S. et al. Determining PD-L1 status in patients with triple-negative breast cancer: Lessons learned from IMpassion130. JNCI: Journal of the National Cancer Institute 114, 664\u201375. https:\/\/doi.org\/10.1093\/jnci\/djab121 (2022).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"61253_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1266843","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. & Ren, J. 18F-FAPI-04 PET\/CT parameters predict PD-L1 expression in esophageal squamous cell carcinoma. Front. Immunol. 14, 1266843. https:\/\/doi.org\/10.3389\/fimmu.2023.1266843 (2023).","journal-title":"Front. Immunol."},{"key":"61253_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00765-y","volume":"11","author":"M Weber","year":"2021","unstructured":"Weber, M. et al. Evaluation of [68Ga]Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. EJNMMI Res. 11, 21. https:\/\/doi.org\/10.1186\/s13550-021-00765-y (2021).","journal-title":"EJNMMI Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61253-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:05:33Z","timestamp":1787133933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61253-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61253"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61253-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical Faculty of the University Hospital Essen (permits no. 20-9485-BO and 19-8991-BO).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants included in the study, as well as for the publication of this study and accompanying images.","order":3,"name":"Ethics","label":"Consent to participate and for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26039"}}